Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

被引：0
|
作者：
McBride, Ali
Campbell, Kim
Bikkina, Mohan
MacDonald, Karen
Abraham, Ivo
Balu, Sanjeev
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3380
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Cost efficiency and budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN):Simulation modeling in metastatic pancreatic cancer
    McBride, Ali
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [12] Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
    Gascon, Pere
    Aapro, Matti
    Ludwig, Heinz
    Bokemeyer, Carsten
    Boccadoro, Mario
    Turner, Matthew
    Denhaerynck, Kris
    MacDonald, Karen
    Abraham, Ivo
    SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 911 - 925
  • [13] Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
    Pere Gascón
    Matti Aapro
    Heinz Ludwig
    Carsten Bokemeyer
    Mario Boccadoro
    Matthew Turner
    Kris Denhaerynck
    Karen MacDonald
    Ivo Abraham
    Supportive Care in Cancer, 2016, 24 : 911 - 925
  • [14] Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
    Aapro, M.
    Ludwig, H.
    Bokemeyer, C.
    Gascon, P.
    Boccadoro, M.
    Denhaerynck, K.
    Krendyukov, A.
    Gorray, M.
    MacDonald, K.
    Abraham, I.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2039 - 2045
  • [15] Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
    Pere Gascón
    Matti Aapro
    Heinz Ludwig
    Carsten Bokemeyer
    Mario Boccadoro
    Matthew Turner
    Kris Denhaerynck
    Karen MacDonald
    Ivo Abraham
    Supportive Care in Cancer, 2016, 24 : 927 - 927
  • [16] Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study
    Ludwig, Heinz
    Bokemeyer, Carsten
    Aapro, Matti
    Boccadoro, Mario
    Gascon, Pere
    Denhaerynck, Kris
    Krendyukov, Andriy
    Abraham, Ivo
    MacDonald, Karen
    FUTURE ONCOLOGY, 2019, 15 (08) : 897 - 908
  • [17] Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer.
    McBride, Ali
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A RETROSPECTIVE COHORT STUDY
    Al Rabayah, A. A.
    Hammoudeh, S.
    Mashni, O.
    Hanoun, E.
    Al Qasem, W.
    AL Momani, D.
    VALUE IN HEALTH, 2018, 21 : S20 - S20
  • [19] MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis
    Gascon, Pere
    Krendyukov, Andriy
    Hoebel, Nadja
    Aapro, Matti
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (03) : 241 - 246
  • [20] A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation
    Zecchini, Julia
    Yum, Kendra
    Steinberg, Amir
    Smith, Cardinale
    Kim, Sara
    SUPPORTIVE CARE IN CANCER, 2018, 26 (03) : 1013 - 1016
12345